Compare Quest Diagnostics Inc (DGX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KLA Corp. — how do they compare? Quest Diagnostics Inc trades at $230.57 (market cap $25.48B), while KLA Corp. trades at $195.89 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 10.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and KLA Corp. for 60 Days on average.
| DGX | KLAC | |
|---|---|---|
Market Cap | $25.48B | $256.72B |
Volume | 941,866 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $247.45 | $301.71 |
52-Week Low | $173.49 | $98.28 |
Typical Hold Time | 56 Days | 60 Days |
Enterprise Value | $31.23B | $257.97B |
Dividend Yield | 1.49% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical support at $194 and resistance at $198. The company demonstrates robust fundamentals with revenue growth from $9.8B in 2024 to $12.16B in 2025 and net income margin expanding to 35.57%. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.05 surpassing the $1.00 estimate. AI-driven demand is fueling backlog growth to $12.57B, positioning KLAC for continued expansion in semiconductor equipment markets.
KLAC presents a compelling growth opportunity with strong analyst support (28 buys vs 2 sells) and a $223.88 consensus price target offering 14% upside. However, elevated valuation ratios (P/E 53.75, P/S 19.12) and competitive pressures from Applied Materials and ASML represent key risks. The stock's technical bullish signal and institutional accumulation support near-term momentum, though margin compression and semiconductor cycle volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
